Moderna's $500K Cancer Shot and Regulatory Capture

Key Takeaways

• Moderna's market valuation tripled from $20 billion to $60 billion after positive trial readouts for its personalized melanoma mRNA therapy.
• The treatment works by sequencing a patient's tumor DNA to identify unique neoantigens, then printing matching mRNA instructions for the immune system.
• The underlying neoantigen research originated in the 1990s and received heavy funding through public National Institutes of Health (NIH) grants.
• David Friedberg argues Moderna's planned $500,000 price tag reflects regulatory capture rather than manufacturing cost, since printing mRNA is inherently cheap.

How Personalized Neoantigen Therapy Works

The science behind the new cancer treatments is direct. Instead of blasting healthy tissue with broad chemotherapy, personalized therapy turns the body against the specific tumor.

“This goes back to the '90s where there was this idea that you could create what are called neoantigens,”▶ 1:23:17 Friedberg explains. A doctor takes a biopsy of the patient's melanoma, isolates the DNA, and runs it through a sequencer. “You multiply the DNA by millions or billions of times. You put all that DNA in a DNA sequencer, it gets chopped up and read. And then the sequence data comes back and it says, 'This is what makes this cancer unique. It's this little sequence of the DNA.'”▶ 1:25:29

Once the computer identifies the mutation, synthesizing the fix takes days. “And mRNA is a really effective way of doing this,”▶ 1:32:35 says Friedberg. “It's super cheap because you don't have to go make all the protein outside the body. You can literally just print the mRNA and get one shot and you're done.”▶ 1:32:38

The mRNA enters the patient's cells, translates into the exact neoantigen protein found on the cancer, and trains the immune system to hunt down and kill every matching cell.

Public Science, Private Rents

The scientific progress is real. The economic structure around it is broken.

Moderna saw its valuation surge by $40 billion on the clinical trial results. “I think they went from like a 20 billion market cap to 60 billion market cap on the positive readouts,”▶ 1:23:03 Friedberg noted. Yet the company is signaling a list price near half a million dollars per patient.

“So why is Moderna saying that they're going to charge $500,000 for this? And that's what I think frustrates me about all this,”▶ 1:28:50 Friedberg said.

The high price is not driven by the cost of goods. Sequencing a sample costs hundreds of dollars. Printing a custom mRNA strand costs very little. The core biology was financed decades ago by public taxpayers through NIH grants.

What Moderna bought was not the basic discovery, but the multi-hundred-million-dollar FDA approval process. “And so what I don't like about this story is that a private pharmaceutical company has seen their market cap go from 20 billion to 60 billion cuz they went through this regulatory process to create what in my mind is a form of regulatory capture,”▶ 1:29:29 Friedberg argued.

When the barrier to entry is passing bureaucracy rather than manufacturing complexity, incumbents can charge monopoly rents on open scientific discoveries.

What to Do With This

Map the regulatory moats in your own market before you build. If your product relies on low-cost compute or open scientific protocols, check whether an incumbent can use compliance certification or trial gates to lock down the distribution layer. Build your pricing and defensibility around proprietary distribution channels, not just technical efficiency that a regulated competitor can box in.